about
Non-evidence-based ICD implantations in the United StatesValvular heart disease in patients supported with left ventricular assist devicesClinical commentary on "Certain uncertainty: life after stroke from the patient's perspective"Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure: Who, What, Where, When, and HowRelief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute DecompensatedTorsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons' National Cardiac Database.Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.Linking inpatient clinical registry data to Medicare claims data using indirect identifiers.Variation in perioperative vasoactive therapy in cardiovascular surgical care: data from the Society of Thoracic Surgeons.Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients.Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines.Incremental value of clinical data beyond claims data in predicting 30-day outcomes after heart failure hospitalization.Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failureOutcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure.GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure.Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary studyAssociation between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%.Postoperative inotrope and vasopressor use following CABG: outcome data from the CAPS-care studyCardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program.Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit.Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies.Outcomes of medicare beneficiaries with heart failure and atrial fibrillation.Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD Registry and ADHERESex differences in medical care and early death after acute myocardial infarction.Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program.Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke.Relation of dyspnea severity on admission for acute heart failure with outcomes and costs.Weekend hospital admission and discharge for heart failure: association with quality of care and clinical outcomes.Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and designPatterns of care quality and prognosis among hospitalized ischemic stroke patients with chronic kidney disease.In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilizationCharacterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry.Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke.Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study.Utility of socioeconomic status in predicting 30-day outcomes after heart failure hospitalization
P50
Q24607930-E85AC671-049A-44EB-8A6E-84E1F842080CQ26992365-EFBF93B6-2B81-4725-9572-0545270A6236Q26996027-507BE681-0856-47D9-909C-81DF68E7782CQ27012929-540680DF-CBA1-4C77-86A6-730D2E482F66Q27340297-4A8E29BA-1F2C-47F7-A3AE-A583C22284A7Q28271500-6176C558-CA72-477B-A9DA-01EC43D787B7Q33291493-FA232E5F-FA45-4AC4-8608-3F5BB9F96F59Q33403964-13DD446B-3F1D-46DD-A6E6-61BAE69F93DAQ33451323-1CFAC575-8B67-4244-8C7E-75C03728A45DQ33470943-52E230A1-1DCE-4D21-B085-DC6587396715Q33572449-57118F9F-F4E2-4A47-8FF2-5689AE96E432Q33764415-6CDBF357-8EAC-456A-936B-83F0622A9785Q33765427-A9AB53E2-7186-4FFA-8176-3B083E7E76BBQ33828109-3DE58A09-B2FD-4192-96C6-786905D3B2A2Q33828157-CA2DB0D2-9865-4C10-86B9-682B567414BEQ33896763-934AA7DC-724A-4D33-AD8A-A8CA5B9D160BQ33917887-B2DB69DC-B00B-4A4E-A1A4-CAE617CDB748Q33956698-5191ED1E-25B2-4ED2-851F-5DF6910A80E8Q33964843-11F12EB0-9D32-41EE-945F-A86A15BBEDA0Q33992679-5C071409-FDC3-4561-800B-A81ED2F14EE0Q34004114-77B0CA0B-880E-46FD-98D8-CC62F9736662Q34032438-C266F094-E77B-453A-A861-7CFEDD3E91AEQ34046332-F2342A2A-6CD0-4259-9F76-EBABE203EA62Q34140489-66EF7FF4-D1B3-4735-BB0A-137A33D94A2BQ34198106-A68F14B8-2C15-4900-AF44-A4130E617B22Q34205257-2543AFCA-CC7F-4534-8C1C-887C6843E4DAQ34239954-ADD4234F-EC23-4A3E-B332-18D308488E16Q34572313-A95FF337-2532-44C5-8E64-65BF739879A8Q34601476-34CF20D4-5A5C-4B44-B240-481C7D9B51B5Q34611350-F36B8685-E32D-421F-943C-569BEC4A27ECQ34617016-39BC1B03-A586-4FDA-A6F1-9F6539AED90CQ34675031-62B88653-2330-42C7-9B66-9FE73D8FD1F7Q34998909-931DE99D-7865-41C8-B3E4-A132D8956DBEQ35005829-3CCE2521-C501-4723-96F7-07D3210ECE3EQ35021961-38673173-1BDD-4FCD-AC09-8A80BD30CAEEQ35026394-DAD50CB0-294A-461B-AD80-2C08CF5397DAQ35170235-C9802F85-531D-4E6D-9195-02A8F1888971Q35221663-7F52DC6B-0D47-41D6-B107-A096226CF17DQ35251451-E1186A14-75AD-4E86-B0F2-9DC277510BB7Q35629747-54043989-83C5-47C6-B9A6-A8B9026214DC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adrian F. Hernandez
@ast
Adrian F. Hernandez
@en
Adrian F. Hernandez
@es
Adrian F. Hernandez
@nl
type
label
Adrian F. Hernandez
@ast
Adrian F. Hernandez
@en
Adrian F. Hernandez
@es
Adrian F. Hernandez
@nl
prefLabel
Adrian F. Hernandez
@ast
Adrian F. Hernandez
@en
Adrian F. Hernandez
@es
Adrian F. Hernandez
@nl
P1053
A-7818-2016
P106
P1153
7401831506
P21
P31
P3829
P496
0000-0003-3387-9616